Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | RORA | P35398 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | RORB | Q92753 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600283 | 0.86 | CNR2 (0.56) | CNR2ALDH1A1HPGDCNR1KDM4E | |
| SCHEMBL23148485 | 0.84 | CNR2 (0.67) | CNR2ALDH1A1HPGDCNR1RORC | |
| SCHEMBL15126363 | 0.81 | CNR2 (0.70) | CNR2ALDH1A1HPGDCNR1MAPT | |
| SCHEMBL23148497 | 0.75 | MAPT (0.48) | CNR2ALDH1A1HPGDCNR1KDM4E | |
| SCHEMBL21651447 | 0.74 | LMNA (0.52) | CNR2ALDH1A1HPGDCNR1KDM4E | |
| SCHEMBL30832750 | 0.73 | KDM4E (0.57) | CNR2ALDH1A1HPGDKDM4ENPY5R | |
| SCHEMBL3417160 | 0.73 | KDM4E (0.57) | CNR2ALDH1A1HPGDKDM4ENPY5R | |
| SCHEMBL29370263 | 0.73 | KDM4E (0.57) | CNR2ALDH1A1HPGDKDM4ENPY5R | |
| SCHEMBL23148488 | 0.72 | MAPT (0.55) | CNR2ALDH1A1HPGDKDM4ENPY5R | |
| SCHEMBL22828642 | 0.71 | CNR2 (0.65) | CNR2ALDH1A1HPGDCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220380367-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | THE UNIVERSITY OF MONTANA | 2022-12-01 | — | — | US | disclosed |
| US-20220380367-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | THE UNIVERSITY OF MONTANA | 2022-12-01 | — | — | US | disclosed |
| US-11420967-B2 | Modified carbazoles as therapeutic agents | UNIVERSITY OF WASHINGTON (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210094949-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | THE UNIVERSITY OF MONTANA | 2021-04-01 | — | — | US | disclosed |
| US-20210094949-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | THE UNIVERSITY OF MONTANA | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380367-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, TUBA1C | CNR2 2189/4885ALDH1A1 3841/4885HPGD 4123/4885 |
| US-20210094949-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, TUBA1C | CNR2 2189/4885ALDH1A1 3841/4885HPGD 4123/4885 |
| US-11420967-B2 | Modified carbazoles as therapeutic agents | TUBB3, TUBB1, TUBA1C | CNR2 2189/4885ALDH1A1 3841/4885HPGD 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.